Research
Hormonal
PPARγ2, but not PPARγ1, plays the key role in adipogenic differentiation, as evidenced by the failure of cells with reduced PPARγ2 to differentiate and the inability of PPARγ1 to restore it.
Not all forms of PPARγ are equal. The specific PPARγ2 isoform is the critical driver of fat cell formation, which has implications for drug design targeting this specific pathway.
GoodSupportsHIGH confidence
PPARγ2, not PPARγ1, plays a key role in adipogenesis... cells with a 95% reduction in PPARγ2 expression failed to undergo adipogenic differentiation, but exogenous delivery of PPARγ2 into the cells restored adipogenic differentiation
Why this rating
Supported by specific in vitro studies using zinc finger repressors.
Source
Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules
Dorothy Moseti et al. · International Journal of Molecular Sciences · 2016
DOI 10.3390/ijms17010124
narrative_reviewCited 749×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- PPARγ is the master regulator of adipogenesis; its presence is necessary and sufficient for the differentiation of precursor cells into mature adipocytes, whereas its absence prevents fat cell formation.Strong
- Several factors, including KLF2, GATA2/3, Pref-1, TAZ, and SIRT1, negatively regulate adipogenesis by inhibiting PPARγ and C/EBPα expression, thereby preventing the formation of mature adipocytes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →